Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

62.06 -0.57 (-0.90%)
Streaming Delayed Price Updated: 1:39 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
78 79 Next >
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
Via Benzinga
Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss
Novo Nordisk's stock is spiraling downwards, with technical analysis revealing a concerning picture of bearish momentum. Short-term opportunities may arise, but the broader downtrend remains strong. 
Via Benzinga
Dow Up 752 Points, Extending Rebound From Dramatic Losses
The Dow Jones Industrial Average is in rally mode, reversing its premarket losses to jump 752 points after yesterday snapping its 10-day losing streak. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for. 
Via The Motley Fool
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review
Micron, Vertex, Novo Nordisk and Nike were notable losers on news. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Novo Nordisk's Options Frenzy: What You Need to Know
Via Benzinga
Market Whales and Their Recent Bets on NVO Options
Via Benzinga
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted. 
Via Benzinga
US Steel Issues Weak Q4 Outlook, Joins Novo Nordisk And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Eli Lilly and Viking Therapeutics jumped on Novo's setback. 
Via Investor's Business Daily
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
Novo Nordisk's REDEFINE 1 trial shows CagriSema delivers significant weight loss and a favorable safety profile in obesity treatment. 
Via Benzinga
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Elon Musk Vs. RFK Jr.: Obesity Crisis Debate Sparks Struggle For Trump's Influence
Debate over tackling U.S. obesity epidemic sparks contrasting views from Trump's orbit: lifestyle changes vs. easier access to weight-loss drugs. 
Via Benzinga
Topics Government
Exposures Political
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List
Compounders now have until late March to wind down their operations, depending on their licensing. 
Via Investor's Business Daily
Exposures Product Safety
Got $250? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
21% of Warren Buffett's "Secret" Portfolio Is Invested in These 3 ETFs. Are They Great Picks for 2025?
Via The Motley Fool
Topics ETFs
This Is Huge News for Eli Lilly Investors
Eli Lilly just gave investors several reasons to cheer. 
Via The Motley Fool
Lennox To Join S&P 500 Index, Replacing Catalent
Lennox, an AI cooling play, will join the S&P 500 before the open on Dec. 23. Bill Holdings will take its pace in the S&P Midcap 400. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease
New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss. Danish Medicines Agency calls for European review. 
Via Benzinga
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease. 
Via MarketBeat
Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug
Via The Motley Fool
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025. 
Via Investor's Business Daily
Novo Nordisk Short
My March $115 puts on NVO​​​​​​​ are still in the green, although less so with Friday’s bounce. My faith in that well-formed H&S top is unshaken, however, so I am planning to hold on tight until the... 
Via Talk Markets
Topics Stocks / Equities
5 Top European Stocks to Buy Before 2025
With the U.S. stock market reaching all-time highs, it might be a good idea to check out some quality European stocks. 
Via The Motley Fool
Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
Novo Nordisk unveils a $1.2 billion production facility in Denmark and finalizes Catalent acquisition, with financial and operational impacts ahead. 
Via Benzinga
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Via The Motley Fool
Novo Nordisk's Ozempic Potentially Linked To Rare Vision Loss Risk, But Absolute Risk Is Low: Study
Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study shows a low absolute risk despite significant association. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.